Related Experiment Video
Updated: Jul 30, 2026
07:35
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
Published on: May 15, 2011
Gene therapy in cardiovascular disease. Current status
S C Francis1, M J Katovich, C H Gelband
1Department of Physiology, College of Medicine, University of Florida Brain Institute, Gainesville, Florida, USA.
American Journal of Pharmacogenomics : Genomics-Related Research in Drug Development and Clinical Practice
|August 14, 2002
Summary
Gene therapy presents a promising new strategy for treating cardiovascular diseases by targeting underlying causes, not just symptoms. Advances in vector technology are key to its potential in both genetic and acquired vascular and cardiac conditions.
Area of Science:
- Cardiovascular Medicine
- Molecular Biology
- Biotechnology
Background:
- Cardiovascular diseases (CVDs) are a major cause of death and illness globally.
- Conventional treatments often fail to address the root causes of CVDs.
- Gene therapy offers a novel therapeutic avenue for CVDs.
Purpose of the Study:
- To explore the potential of gene therapy in preventing and treating cardiovascular diseases.
- To review the advancements in gene transfer techniques for cardiovascular applications.
- To assess the efficacy of gene therapy in various cardiovascular conditions.
Main Methods:
- Utilizing viral vector systems and fusigenic liposome vectors for gene delivery.
- Evaluating gene transfer techniques in animal models for vascular and myocardial applications.
- Assessing gene therapy for genetic and acquired cardiovascular disorders.
Main Results:
- Technical progress in vector systems has enabled effective gene therapy strategies.
- Gene transfer techniques show promise for treating conditions like familial hypercholesterolemia, atherosclerosis, heart failure, and hypertension.
- Studies in both animal models and humans demonstrate the potential of gene therapy.
Conclusions:
- Gene therapy is a promising strategy for cardiovascular disease treatment.
- Continued technological advancements are crucial for realizing the full potential of cardiovascular gene therapy.
- Gene therapy offers a targeted approach to address the underlying causes of cardiovascular disorders.
Related Concept Videos
00:59Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...